A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33418036

about

Novel agents in the treatment of multiple myeloma: a review about the future Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer The Role of Immunotherapy in Multiple Myeloma Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Development of Novel Immunotherapies for Multiple Myeloma Siltuximab (CNTO 328): a promising option for human malignancies The role of SLAMF7 in multiple myeloma: impact on therapy.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Clinical development of siltuximab.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.Emerging antibodies for the treatment of multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.Economic burden of relapsed or refractory multiple myeloma: Results from an international trial.Monoclonal antibody therapy in multiple myeloma.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment.Emerging drugs and combinations to treat multiple myeloma.Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Immunotherapy Strategies Against Multiple Myeloma.Emerging immune targets for the treatment of multiple myeloma.The bone-marrow niche in MDS and MGUS: implications for AML and MM.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.Antibody based immunotherapy for multiple myeloma: it's about time.Interleukin-6 role in head and neck squamous cell carcinoma progression.Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer

P2860

Q26745924-C58F64E3-F842-4951-827F-872AFB3F7C9B Q26769917-EF5D4F2C-ECE5-4D44-8A6B-A72BBC4A724F Q26771144-817E8DA3-76DE-4D4F-8912-0882D8857343 Q26799104-B37B6571-5C70-4C0C-8663-712A7A49939A Q27023599-44904E4D-5DF0-4BD9-91ED-8925354C2D00 Q27026478-33FC8F89-8941-4A0E-8E86-A763C0D3418B Q28066890-031BB493-6813-492B-AF71-987C63A67E57 Q28082572-45F239E8-B754-4FFB-B02E-1A72099E0876 Q30249167-DADA10AF-A42D-4147-9A6E-DAAC650D628B Q30275870-01F1B5A9-8C5A-45DB-B6D9-4E99B217AACB Q33429980-036197A2-DEE9-4068-AA77-37477E99AE38 Q36150377-1499BCAC-454E-4C4C-889B-5670FE673F38 Q37384918-1DCEFE3E-3E6C-41CF-AA18-317D032EF665 Q37722551-D919920F-0AB3-46D1-AC76-4F412BCC1DFA Q38336406-DA9F6C4E-D3A8-4408-ABF1-DAFC1FD42F36 Q38489678-2A6DBC5A-C6F2-446A-93A5-0E4EE4C05C68 Q38601582-6F932A9C-80A6-4E7B-9CBD-00B2EDCBA603 Q38658328-B3CA7AF8-99A4-46DA-BFBD-DA2FE176AE88 Q38728585-FBDBB146-5CED-4EA7-AF79-71736958864F Q38763837-7FEF3C26-3BB3-4002-BC8D-B8581CEDFE23 Q38838239-AC4B12CB-E14E-4421-B767-94D8502B134B Q38853857-0C2C6626-EDBB-46BC-93F6-466561BA3644 Q38901317-0F1D6EC8-33A3-480B-8699-9DC15852E3DA Q38956372-DA5656C6-10D6-4F4D-B837-DAEA60AF359F Q39381251-A6C99A8E-F6ED-4894-8C52-1A88C099B320 Q39390630-995D6DDF-CFAF-451C-A8FB-2620433D9E30 Q41694198-724B4012-02EA-4D74-8DA5-233CDD310ADB Q42288627-E1F829AB-7D33-4EAB-BD8E-E286A4D28D5A Q47112048-1EA055DE-6ACE-484E-8692-BB616A06FCA0 Q47409821-0AA664C0-6638-4A02-8249-24FDC6EDD450 Q48176112-57D0AE31-5680-4854-B583-061A6724E4A8 Q49539698-1C64DF95-2655-482E-913B-8E003167DAB0 Q49995864-D30B103A-278A-4503-A4D0-165BBE0B534E Q50025144-3E94B33D-92D8-4D76-8BBF-3F51EB6771EB Q50114615-A971B653-02A1-45AF-976F-13465435EE7C Q50191433-5F0E39CA-AA8F-4EE8-9DDD-20C658585306 Q52540247-498A60AB-F181-4F24-BD5E-C1812A43904C Q53349911-D6C12EFA-F17B-4736-AC2D-595F78C39FE7 Q55031288-AEA23B58-1797-4107-95C6-CC68DD3731DC Q57115352-D0118A63-CF15-485C-BFBE-BDAE6C1BED44

P2860

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33418036

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@ast

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@en

type

label

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@ast

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@en

prefLabel

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@ast

A phase 2, randomized, double- ...... r refractory multiple myeloma.

@en

P1433

Q33418036-F60179ED-6B85-4C42-AA5E-04C0A2871F45

P1476

Q33418036-D803A129-2291-4117-93C1-4990762C36CF

P2093

Q33418036-22CF9427-EC91-41E2-BD48-AF589A7785D9

Q33418036-67BB4035-079C-4DBC-85CE-AE4280B42DB9

Q33418036-77B70236-2637-4258-A394-8F0FBDB1BACF

Q33418036-783844BA-C95E-4743-AF71-3FAE1998CD1B

Q33418036-7AB8402A-1CFF-4E0C-B493-59AF2143B0CD

Q33418036-8DD1C4CD-A4D5-4C15-8877-8DCC30B6311B

Q33418036-8E7C1D90-718E-4065-BD11-C06785218994

Q33418036-A64FF005-44FE-49C8-A17F-0CFE37D0BC08

Q33418036-AEA3C217-F328-4C37-A383-168A3B1F5414

Q33418036-B845A4AB-619C-4E74-B1A2-E670E8B09178

P2860

Q33418036-03258D0F-2351-4A6D-AE7E-2A7ACB1E1F34

Q33418036-0AE5A8EF-999B-4FB5-846F-6EE38F3C9F55

Q33418036-157C9D29-44CD-497E-881D-06DDE448ADAC

Q33418036-2236BDE9-A1AB-4981-9660-CE0A673D3AC4

Q33418036-24C3A89B-2C90-4349-BB15-C14B8239FA4E

Q33418036-2B8165B5-34B1-46A3-8CDE-0C26F2803900

Q33418036-3249813B-8537-49D4-A661-95C0EF7847F5

Q33418036-331C1B19-6C1B-43BE-B343-31319CCC2A42

Q33418036-47CBF5C3-C3EF-4325-85EE-2857A3596B8A

Q33418036-4A82DD61-34B1-449C-9AD9-D87A3D3E6BD9

P304

Q33418036-61844ABD-5809-489A-9A17-B83BBBA78BA7

P31

Q33418036-50084166-F594-449E-A326-67377F03FBD9

P356

Q33418036-E6618AF7-6F59-45C8-B026-E3A0CAE69EEF

P433

Q33418036-D763B090-0E87-4105-9004-8E46AE3B4EBB

P478

Q33418036-4650E1C4-E6BD-4ECE-9820-1894CF63FAF0

P50

Q33418036-2573DB8A-1380-4236-9409-B3705D177F94

Q33418036-408E2A9E-2225-4903-A7D8-0E7625DE64D8

Q33418036-50A7C582-C422-4E10-A1EC-DFD1D01C4AA5

Q33418036-99DF5662-8C56-45E0-93DB-59DEEBECAAF8

Q33418036-B156E8BB-BF16-4BFF-B4EC-C187FD108067

Q33418036-FE85BA85-2A2B-4788-876D-E39A3CAE1FBA

P577

Q33418036-16646672-112D-40CC-B13D-C134F5292C4A

P5875

Q33418036-DE9C63E4-F476-40EF-BD91-88A4D4946880

P698

Q33418036-5E420D80-8B82-4840-8330-C1851B3E994C

P921

Q33418036-0FB92F9F-28F3-4565-A848-7FD4E4CED2F9

P932

Q33418036-AA15A4A1-081C-457E-A661-6AB7F341E19A

P356

P1433

American Journal of Hematology

P1476

A phase 2, randomized, double- ...... or refractory multiple myeloma

@en

P2093

Alexander Suvorov

http://www.w3.org/2001/XMLSchema#string

Angelo Maiolino

http://www.w3.org/2001/XMLSchema#string

Cathy Williams

http://www.w3.org/2001/XMLSchema#string

Heather Sutherland

http://www.w3.org/2001/XMLSchema#string

Helgi van de Velde

http://www.w3.org/2001/XMLSchema#string

Hong Xie

http://www.w3.org/2001/XMLSchema#string

James D Cavenagh

http://www.w3.org/2001/XMLSchema#string

Jean-Franςois Rossi

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

Manjula Reddy

http://www.w3.org/2001/XMLSchema#string

P2860

Pain assessment: global use of the Brief Pain Inventory

Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

International staging system for multiple myeloma.

P304

42-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.23868

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Robert Z Orlowski

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266621782

http://www.w3.org/2001/XMLSchema#string

P698

25294016

http://www.w3.org/2001/XMLSchema#string

P921

P932

4737504

http://www.w3.org/2001/XMLSchema#string